ICLUSIG (ponatinib) CML 5-year efficacy data

PACE TRIAL DATA

PACE trial design

PACE was a single-arm, open-label, international, multicenter, phase 2 trial studying ICLUSIG in adult patients with CML or Ph+ ALL that was resistant or intolerant to a prior kinase inhibitor, or who had T315I mutation (n=449).1,3

In PACE, patients received a starting dose of ICLUSIG 45 mg orally once daily (N=449; n=270 CP-CML, n=85 AP-CML, n=62 BP-CML, n=32 Ph+ ALL).1,3
Clinical trial design for patients with CP-CML receiving ICLUSIG (ponatinib) 45 mg, showing subgroups of resistant/intolerant and T315I+ patients over a median 5-year follow-up.
aThree patients who had not received prior dasatinib or nilotinib did not have T315I confirmed at baseline and were not evaluable for efficacy.1

bDose reductions to 15 mg once daily or 30 mg once daily were applied to patients with and without MCyR, respectively, and were applied to manage AEs, or implemented proactively following an accumulation of AOEs.1,2
cResistance in CP-CML while on prior TKI therapy was defined as failure to achieve either a CHR (by 3 months), a minor cytogenetic response (by 6 months), or a MCyR (by 12 months). Patients with CP-CML who experienced a loss of response or development of a kinase domain mutation in the absence of a CCyR or progression to AP-CML or BP-CML at any time on prior TKI therapy were also considered resistant. Intolerance was defined as the discontinuation of prior TKI therapy due to toxicities despite optimal management in the absence of a CCyR in patients with CP-CML or MaHR for patients with AP-CML, BP-CML, or Ph+ ALL.1

Follow-up for trial at 40.5 months1

At study completion, the median duration of follow-up for the trial (all cohorts) was 40.5 months (range: 0.1 months to 79.5 months)1

Efficacy measure of  MCyR by 12 months1,a

The major efficacy outcome measure (primary endpoint) for patients with chronic-phase chronic myeloid leukemia was MCyR by 12 months, which included CCyR and PCyR1,a

Dose reductions to manage
adverse reactions2,b

Dose reductions to 30 mg or 15 mg once daily were applied to manage adverse reactions, per protocol, or implemented proactively in 20132,b

aPrimary endpoint was MCyR by 12 months for CP-CML and MaHR by 6 months for AP-CML, BP-CML, or Ph+ ALL. Secondary endpoints included major molecular response (MMR), time to and duration of response, progression-free survival (PFS), overall survival (OS), and safety.2  
b15 mg once daily for CP-CML patients with MCyR, and 30 mg once daily for CP-CML patients without MCyR, AP-CML, and BP-CML patients.2

Patient characteristics 

Patients with CP-CML in the PACE trial had highly-resistant disease—80% of patients were resistant* to prior TKI therapy and 24% had at least one BCR::ABL1 mutation1,2

Baseline characteristics table comparing CP-CML, AP-CML, and BP-CML patient cohorts.

Response rate: At enrollment, few study patients had previously responded to a prior tyrosine kinase inhibitor³

Best response to any treatment prior to ICLUSIG2,a
Best response rates to any treatment prior to ICLUSIG (ponatinib) in the PACE trial, including 26% achieving MCyR or better and 3% achieving MMR.
aMost recent regimen containing dasatinib or nilotinib.1,3

In PACE, TKI-resistant patients achieved deep, clinically significant responses and high rates of MMR¹

Proven long-term benefit in patients with TKI-resistant CP-CML (n=267)1
Proven long-term benefit in patients with TKI-resistant CP-CML. 55% achieved MCyR by 12 months and 40% achieved MMR at any time.

ICLUSIG achieved a deep and durable response over 5 years in patients with CP-CML, TKI resistance, and the T315I mutation¹

Achieved MCyR by 12 months %1
ICLUSIG (ponatinib) achieved MCyR by 12 months in 55% of the total CP-CML population, 51% of resistant/intolerant patients, and 70% of T315I patients.
  • Median duration of treatment for CP-CML patients was 35 months1
     
In PACE, ICLUSIG provided durable, clinically meaningful responses in TKI-resistant CP-CML patients, including those with the T315I mutation.1 

ICLUSIG demonstrated efficacy patients with AP- and BP-CML with resistant or intolerant advanced disease¹

Efficacy of ICLUSIG in patients with resistant or intolerant advanced disease 
(includes R/I and T315I cohorts) in PACE1
ICLUSIG (ponatinib) hematologic response rates: 57% MaHR and 51% CHR for AP-CML, and 31% MaHR and 21% CHR for BP-CML.
aPrimary endpoint for patients with AP-CML, BP-CML, and Ph+ ALL was MaHR by 6 months, which combines complete hematologic responses and no evidence of leukemia.1

bCHR: WBC ≤ institutional ULN, ANC ≥1000/mm3, platelets ≥100,000/mm3, no blasts or promyelocytes in peripheral blood, bone marrow blasts ≤5%, <5% myelocytes plus metamyelocytes in peripheral blood, basophils <5% in peripheral blood, no extramedullary involvement (including no hepatomegaly or splenomegaly).1

Patients in PACE achieved and sustained responses¹

Median time to MaHR1
Median time to MaHR with ICLUSIG (ponatinib) was 0.8 months for AP-CML and 1 month for BP-CML.
Median duration of MaHR1
Median duration of MaHR with ICLUSIG (ponatinib) was 14 months for AP-CML and 6.5 months for BP-CML.

View safety profile in PACE trial

View ICLUSIG mechanism of action

AOE=arterial occlusive events; AP-CML=accelerated-phase chronic myeloid leukemia; BP-CML=blast-phase chronic myeloid leukemia; CCyR=complete cytogenetic response; CHR=complete hematologic response; CI=confidence interval; CML=chronic myeloid leukemia; CP-CML=chronic-phase chronic myeloid leukemia; ECOG PS=Eastern Cooperative Oncology Group performance status; MaHR=major hematologic response; MCyR=major cytogenetic response; MMR=major molecular response; OS=overall survival; PCyR=partial cytogenetic response; PFS=progression-free survival; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; QD=once daily; TKI=tyrosine kinase inhibitor.

CML Patient Profiles

""

CML resources and support

""